WGS
Get informed when a big investor buys or sells
+ FollowOvervalued by 260.5% based on the discounted cash flow analysis.
| Market cap | $2.57 Billion |
|---|---|
| Enterprise Value | $2.68 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.73 |
| Beta | 1.98 |
| Outstanding Shares | 29,710,139 |
| P/E Ratio | -23.72 |
|---|---|
| PEG | 8.98 |
| Price to Sales | 5.83 |
| Price to Book Ratio | 10.92 |
| Enterprise Value to Revenue | 5.9 |
| Enterprise Value to EBIT | -39.82 |
| Enterprise Value to Net Income | -26 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.69 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3541▼ 11.72% |
|---|---|
| Total Calls | 838,400▲ 101.83% |
| Total Puts | 296,900▲ 51.63% |
Holdings and activity of institutional investors.
| Ownership % | 113.32%▲ 6.78% |
|---|---|
| Total Invested | $2.20B▲ 9.59% |
| Investors Holding | 239▼ 14.00% |
No data
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and g...